Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Sapheon Closure System Feasibility Study

This study has been completed.
Information provided by (Responsible Party):
Medtronic Endovascular Identifier:
First received: May 18, 2012
Last updated: April 29, 2016
Last verified: April 2016
This is a single center, prospective, non-randomized, feasibility study for the evaluation of safety, efficacy and performance of the Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Condition Intervention
Venous Insufficiency of Leg
Device: Sapheon™ Closure System

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Sapheon Closure System Feasibility Study

Further study details as provided by Medtronic Endovascular:

Primary Outcome Measures:
  • Anatomical Success [ Time Frame: 30 days post procedure ]
    Evaluation of anatomic efficacy will be demonstrated by the absence of flow (Complete Closure) within the treated vein segment as determined by duplex ultrasound examination and will be performed in accordance with a standardized and detailed imaging protocol.

Secondary Outcome Measures:
  • Safety Endpoint [ Time Frame: Through 6 month follow-up ]
    Evaluation of safety will be assessed by the DSMB of all incidence of adverse events (procedure and non-procedure related; serious and non-serious)

Enrollment: 38
Study Start Date: July 2011
Study Completion Date: July 2014
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sapheon™ Closure System
Sapheon™ Closure System for the treatment of incompetent saphenous veins.
Device: Sapheon™ Closure System
Sapheon™ Closure System for the treatment of incompetent saphenous veins.

Detailed Description:

Venous insufficiency of the lower extremities is a very common condition that is influenced by genetic and mechanical factors, and is a chronic and progressive disorder. The primary objectives for this clinical Study are to

  1. demonstrate the safety of the Sapheon™ Closure System for the treatment of incompetent saphenous veins,
  2. demonstrate the early and late efficacy of The Sapheon™ Closure System for the treatment of incompetent saphenous veins, and
  3. demonstrate the satisfactory performance of the Sapheon™ Closure System device components.

Ages Eligible for Study:   21 Years to 76 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or non-pregnant females ≥21 years of age but <76 years of age.
  • Venous reflux disease in the GSV diagnosed by clinical symptoms, with or without visible varicosities, and confirmed by duplex ultrasound imaging.
  • Candidate for surgical closure of a segment of the GSV.
  • CEAP classification of C2, C3 or C4.
  • Ability to walk unassisted.
  • Life expectancy of at least 18 months.
  • Weight >110 lbs. (50 kg).
  • Ability to attend follow-up visits.
  • Ability to understand the investigational nature of the treatment, and to provide written informed consent.

Exclusion Criteria:

  • Previous surgical procedure (surgical, thermal, or chemical ablation) associated with the venous segment to be treated.
  • Diameter of index vein (Supine) <3mm or >12 mm in any segment.
  • Tortuous GSV, which in the opinion of the Investigator will limit catheter placement.
  • Local or systemic infection.
  • Insulin dependent diabetes.
  • Leg obesity impairing the ability to gain access to the treatment leg, and/or apply sufficient compression for treatment.
  • Documented history of superficial or deep thrombophlebitis.
  • Varicosities secondary to pelvic or abdominal tumor.
  • Significant arterial insufficiency; demonstrated by absence of ankle pulse.
  • Known sensitivity to the cyanoacrylate (CA) adhesive or positive reaction just prior to surgery (by injecting a small peripheral vein with the agent). The Study surgeon will judge the need for the injection and the subject's reaction to the injection on clinical grounds.
  • Formal duplication of the saphenous trunk in the index vein (Accessory GSV segments allowed).
  • Hypercoaguable state.
  • Presence of incompetent perforators in the treatment length.
  • History of right ventricular failure.
  • Significant femoral or popliteal vein insufficiency.
  • BMI >35
  • Additional procedures in the treatment leg likely required within the six months after the investigational procedure.
  • Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment.
  • Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the Investigator may prevent safe participation or otherwise render the subject ineligible for the Study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01603433

Dominican Republic
Clinica Canela
Santo Domingo, Dominican Republic
Sponsors and Collaborators
Medtronic Endovascular
Principal Investigator: Claudia Bautista, MD Clinica Canela
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medtronic Endovascular Identifier: NCT01603433     History of Changes
Other Study ID Numbers: CP-10669-01
Study First Received: May 18, 2012
Last Updated: April 29, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Venous Insufficiency
Vascular Diseases
Cardiovascular Diseases processed this record on April 28, 2017